Profarma Distribuidora de Produtos Farmacêuticos S.A.

BOVESPA:PFRM3 Stock Report

Market Cap: R$734.4m

Profarma Distribuidora de Produtos Farmacêuticos Past Earnings Performance

Past criteria checks 2/6

Profarma Distribuidora de Produtos Farmacêuticos has been growing earnings at an average annual rate of 35.5%, while the Healthcare industry saw earnings growing at 12.2% annually. Revenues have been growing at an average rate of 15% per year. Profarma Distribuidora de Produtos Farmacêuticos's return on equity is 5.1%, and it has net margins of 0.8%.

Key information

35.5%

Earnings growth rate

35.6%

EPS growth rate

Healthcare Industry Growth11.6%
Revenue growth rate15.0%
Return on equity5.1%
Net Margin0.8%
Next Earnings Update08 May 2024

Recent past performance updates

Recent updates

Profarma Distribuidora de Produtos Farmacêuticos S.A.'s (BVMF:PFRM3) 28% Price Boost Is Out Of Tune With Earnings

Mar 01
Profarma Distribuidora de Produtos Farmacêuticos S.A.'s (BVMF:PFRM3) 28% Price Boost Is Out Of Tune With Earnings

These 4 Measures Indicate That Profarma Distribuidora de Produtos Farmacêuticos (BVMF:PFRM3) Is Using Debt Extensively

Feb 21
These 4 Measures Indicate That Profarma Distribuidora de Produtos Farmacêuticos (BVMF:PFRM3) Is Using Debt Extensively

Returns On Capital Are Showing Encouraging Signs At Profarma Distribuidora de Produtos Farmacêuticos (BVMF:PFRM3)

Nov 04
Returns On Capital Are Showing Encouraging Signs At Profarma Distribuidora de Produtos Farmacêuticos (BVMF:PFRM3)

Investors Will Want Profarma Distribuidora de Produtos Farmacêuticos' (BVMF:PFRM3) Growth In ROCE To Persist

Aug 03
Investors Will Want Profarma Distribuidora de Produtos Farmacêuticos' (BVMF:PFRM3) Growth In ROCE To Persist

These 4 Measures Indicate That Profarma Distribuidora de Produtos Farmacêuticos (BVMF:PFRM3) Is Using Debt Extensively

Jun 08
These 4 Measures Indicate That Profarma Distribuidora de Produtos Farmacêuticos (BVMF:PFRM3) Is Using Debt Extensively

These 4 Measures Indicate That Profarma Distribuidora de Produtos Farmacêuticos (BVMF:PFRM3) Is Using Debt Extensively

Sep 26
These 4 Measures Indicate That Profarma Distribuidora de Produtos Farmacêuticos (BVMF:PFRM3) Is Using Debt Extensively

Profarma Distribuidora de Produtos Farmacêuticos S.A. (BVMF:PFRM3) Shares Fly 26% But Investors Aren't Buying For Growth

Jan 01
Profarma Distribuidora de Produtos Farmacêuticos S.A. (BVMF:PFRM3) Shares Fly 26% But Investors Aren't Buying For Growth

Here's Why Profarma Distribuidora de Produtos Farmacêuticos (BVMF:PFRM3) Is Weighed Down By Its Debt Load

May 28
Here's Why Profarma Distribuidora de Produtos Farmacêuticos (BVMF:PFRM3) Is Weighed Down By Its Debt Load

Profarma Distribuidora de Produtos Farmacêuticos (BVMF:PFRM3) Might Have The Makings Of A Multi-Bagger

May 07
Profarma Distribuidora de Produtos Farmacêuticos (BVMF:PFRM3) Might Have The Makings Of A Multi-Bagger

How Much Of Profarma Distribuidora de Produtos Farmacêuticos S.A. (BVMF:PFRM3) Do Institutions Own?

Mar 10
How Much Of Profarma Distribuidora de Produtos Farmacêuticos S.A. (BVMF:PFRM3) Do Institutions Own?

Are Profarma Distribuidora de Produtos Farmacêuticos' (BVMF:PFRM3) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Feb 02
Are Profarma Distribuidora de Produtos Farmacêuticos' (BVMF:PFRM3) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Is Profarma Distribuidora de Produtos Farmacêuticos (BVMF:PFRM3) Using Too Much Debt?

Jan 05
Is Profarma Distribuidora de Produtos Farmacêuticos (BVMF:PFRM3) Using Too Much Debt?

What Type Of Shareholders Make Up Profarma Distribuidora de Produtos Farmacêuticos S.A.'s (BVMF:PFRM3) Share Registry?

Dec 10
What Type Of Shareholders Make Up Profarma Distribuidora de Produtos Farmacêuticos S.A.'s (BVMF:PFRM3) Share Registry?

Revenue & Expenses Breakdown
Beta

How Profarma Distribuidora de Produtos Farmacêuticos makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

BOVESPA:PFRM3 Revenue, expenses and earnings (BRL Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 238,662701,0460
30 Sep 238,550478750
30 Jun 238,291318430
31 Mar 238,087828140
31 Dec 227,816819170
30 Sep 227,435877540
30 Jun 227,031967300
31 Mar 226,661636910
31 Dec 216,413786670
30 Sep 216,199956440
30 Jun 215,891996080
31 Mar 215,579605800
31 Dec 205,481525680
30 Sep 205,281445540
30 Jun 205,218165610
31 Mar 205,104215680
31 Dec 194,801125550
30 Sep 194,677-55680
30 Jun 194,513-135810
31 Mar 194,388-125900
31 Dec 184,271-106060
30 Sep 184,066-376110
30 Jun 184,009-656150
31 Mar 184,046-916360
31 Dec 174,101-1136530
30 Sep 174,223-1266480
30 Jun 174,195-1006110
31 Mar 174,149-675610
31 Dec 164,085-495050
30 Sep 163,858-184450
30 Jun 163,780-144150
31 Mar 163,619-233870
31 Dec 153,465-213580
30 Sep 153,471-343550
30 Jun 153,392-483480
31 Mar 153,430-463530
31 Dec 143,449-523640
30 Sep 143,439-373790
30 Jun 143,455-113700
31 Mar 143,45603530
31 Dec 133,470203330
30 Sep 133,453332950
30 Jun 133,394382840

Quality Earnings: PFRM3 has high quality earnings.

Growing Profit Margin: PFRM3's current net profit margins (0.8%) are lower than last year (1%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: PFRM3 has become profitable over the past 5 years, growing earnings by 35.5% per year.

Accelerating Growth: PFRM3's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: PFRM3 had negative earnings growth (-13%) over the past year, making it difficult to compare to the Healthcare industry average (38.6%).


Return on Equity

High ROE: PFRM3's Return on Equity (5.1%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.